Levo Therapeutics Receives Complete Response Letter From FDA for Its New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
Jan 18, 2022
Levo Therapeutics, Inc., a biotechnology company dedicated to using genetic insights to advance treatments for Prader-Willi syndrome (PWS) and related disorders, announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for LV-101 (intranasal carbetocin) as a treatment for hyperphagia, anxiousness, and distress associated with PWS.
FDA's Division of Psychiatry concluded that, while LV-101 appears to be generally safe and well-tolerated, the efficacy data available for the proposed 3.2 mg dose of LV-101 were insufficient for approval. To address this issue, FDA recommended that an additional clinical study be conducted to confirm the results of the 3.2 mg dose. Levo is currently in discussions with FDA regarding the design of this new study and continues to provide carbetocin to existing study patients.
PWS is a rare, complex, neurodevelopmental disorder that occurs in approximately 1 in 16,000 birthsi and is characterized by a false state of starvation and associated hyperphagia (unrelenting hunger), to which a deficiency in oxytocin is believed to be contributoryii. LV-101 is a selective oxytocin-receptor agonist with over 200 patient-years of safety data collected to date in individuals with PWS.
"We are disappointed by the outcome of FDA's review of our application and the continued lack of treatments for the most significant symptoms of the syndrome," said Sara Cotter, CEO of Levo Therapeutics. "We are hopeful that our discussions with FDA regarding the next study will be productive and that we can initiate enrollment of a confirmatory study later this year."
"As the highest enrolling site in both the phase 2 and phase 3 PWS studies of intranasal carbetocin, we have seen the exciting potential of this therapy," said Elizabeth Roof, M.A., of Vanderbilt University. "We are committed to again being a part of the next study of carbetocin and look forward to collecting the data needed to enable access to this important treatment option."
"We remain steadfast in our support of carbetocin and all potential treatments for our community," said Theresa Strong, PhD, founding member and Director of Research Programs at the Foundation for Prader-Willi Research. "We hope that, going forward, FDA will recognize the tremendous unmet need and exercise the flexibility it has when considering new products for rare, serious diseases such as PWS."
"Currently, there are no therapies approved by FDA to treat the most challenging aspects of PWS, namely the constant hunger and distress that substantially impact patients and families," said Paige Rivard, MBA, CEO of the Prader-Willi Syndrome Association USA. "PWSA | USA remains committed to advocating for treatments for the PWS community and we urge the PWS community to consider enrollment in the next study of this important potential treatment."
Caregivers who are interested in being contacted as details become available are encouraged to provide their information at www.pwsstudy.com.
About LV-101 (Intranasal Carbetocin)
Carbetocin is an analog of the naturally occurring neuroendocrine hormone oxytocin. Carbetocin was designed to have an improved receptor-binding profile compared to oxytocin, with greater affinity for the oxytocin receptor and lower affinity for related vasopressin receptors. Through our licensor Ferring Pharmaceuticals, carbetocin is approved in over 100 countries outside the United States for the prevention of uterine atony and excessive bleeding during cesarean section delivery, as well as newly approved in the EU following vaginal birth, with an estimated cumulative exposure of over 11 million patients. LV-101 is an investigational intranasal form of carbetocin, intended to be administered to patients with PWS three times each day with meals. LV-101 has been granted orphan drug and Fast Track designations from the FDA.
About Prader-Willi Syndrome (PWS)
Prader-Willi syndrome is a complex, multisystem neurodevelopmental disorder that occurs in approximately 1 in 16,000 births.i The underlying cause of PWS is the lack of expression of paternally inherited imprinted genes on chromosome 15q11-q13. These genetic anomalies lead to a distinctive phenotype that includes mild to moderate levels of intellectual disability, compulsivity, growth hormone deficiency, life-threatening hyperphagia, and anxiety.
About Levo Therapeutics, Inc.
Levo Therapeutics is a biotechnology company dedicated to using genetic insights to advance treatments for Prader-Willi syndrome and related disorders. To learn more about Levo, visit www.levotx.com or follow on Twitter and LinkedIn.
For Further Information:
Levo Therapeutics, Inc.
Tel: 847-901-9260
[email protected]
i Burd L, Vesely B, Martsolf J, Kerbeshian J. Prevalence study of Prader-Willi syndrome in North Dakota. Am J Med Genet. 1990; 37:97-9.
ii Swaab, D. F., J. S. Purba, and M. A. Hofman. "Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases." The Journal of Clinical Endocrinology & Metabolism 80.2 (1995): 573-579.
Press Release Service by Newswire.com
Original Source: Levo Therapeutics Receives Complete Response Letter From FDA for Its New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
More News
Channel Islands fuel prices set to rise again
The increases could mean mean diesel costing more than £2 per litre.
US ban on Canadian alcohol and dairy comes into effect as trade war drags on
It is the latest escalation in the Canada-US trade war after negotiations collapsed in late August, with no word on when talks may resume.
US Hits Canada With Ban on Some Dairy and Liquor Products
An outright ban on certain Canadian products took effect Tuesday, escalating a damaging trade fight between the two North American allies.
For Japan’s Young Singles, Romance Gets a Corporate Middleman
A generation exhausted by dating apps is embracing a corporate reinvention of traditional matchmaking, fueling an industry that promises a fast track to marriage.
CNN, MS NOW and Politico Seek a Longer Reprieve From White House Ban
A federal court temporarily lifted the ban last week. The outlets want a longer pause while they sue to restore their access.
China and the U.S. Pledge to Cut Tariffs on $60 Billion in Goods
The two countries unveiled separate lists covering thousands of products as they sought to ease trade tensions and stabilize relations before further negotiations.
Smart Headlights Finally Trickle Down to Cars in the U.S.
Federal data shows that half of all traffic fatalities happen after dark, but only one-quarter of driving happens at night. So any help is welcome.
Women Sluggers Are No Longer in a League of Their Own
As a group of players from an all-women’s baseball league in the 1940s and ’50s gathered at a recent reunion, the future of women’s baseball looks bright again.
Why UK diesel prices have hit an all-time high
The average price of a litre of diesel at the pump stands at 198.32p, according to the RAC motoring body.
UK diesel price hits all-time high, the RAC says
The US-Israel war with Iran has caused fuel prices to soar due to disruption of global oil supplies.
Nvidia Adds $150 Billion to Massive Stock Buyback, the Largest Ever
The increase comes four months after the chip giant added $80 billion to its buyback program, bringing the total remaining authorized amount to $235 billion.
Oil Prices Climb on Continued Impasse in U.S.-Iran Talks
President Trump rejected Iran’s proposal over the weekend, calling it “unacceptable,” but Iran said it was still waiting for “definitive news” from Washington.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.